June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Demographic Subgroup Analysis in a Study Comparing the Additive Effect of Brinzolamide 1%/Brimonidine 0.2% in Patients with Open-Angle Glaucoma or Ocular Hypertension Treated with TRAVATAN Z® (NCT01937299)
Author Affiliations & Notes
  • Gregory Katz
    Department of Ophthalmology, St. Joseph Mercy Medical Center, Ann Arbor, MI
  • Matthew Mcmenemy
    Lone Star Eye Care, P.A., Sugar Land, TX
  • Douglas Hubatsch
    Alcon Laboratories, Inc., Fort Worth, TX
  • Tony Realini
    Department of Ophthalmology, West Virginia University, Morgantown, WV
  • Robert M Feldman
    Department of Ophthalmology and Visual Sciences, Robert Cizik Eye Clinic, University of Texas Health Science Center, Houston, TX
  • Footnotes
    Commercial Relationships Gregory Katz, Alcon (C), Alcon (R); Matthew Mcmenemy, Alcon (C), Alcon (F), Alcon (R), AMO (F), Bausch & Lomb (C), Ideal Implant (I), Nicox (C); Douglas Hubatsch, Alcon (E); Tony Realini, Alcon (C), Lumenis (F); Robert Feldman, Alcon (C), Alcon (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5700. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Gregory Katz, Matthew Mcmenemy, Douglas Hubatsch, Tony Realini, Robert M Feldman; Demographic Subgroup Analysis in a Study Comparing the Additive Effect of Brinzolamide 1%/Brimonidine 0.2% in Patients with Open-Angle Glaucoma or Ocular Hypertension Treated with TRAVATAN Z® (NCT01937299). Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5700.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Brinzolamide 1%/Brimonidine 0.2% fixed combination (BBFC) has been shown to provide superior IOP-lowering efficacy when added to TRAVATAN Z® in comparison to TRAVATAN Z® monotherapy in a recently completed study.1 In this report, subgroups based on age, race and gender have been analyzed to detect differences in efficacy of BBFC+TRAVATAN Z® as compared to TRAVATAN Z®.<br /> 1Abstract submitted to American Glaucoma Society 2015.

 
Methods
 

NCT01937299 was a 2-arm, phase 4, randomized, double-masked study that evaluated the additive effect of BBFC in patients on TRAVATAN Z® monotherapy. The primary efficacy endpoint was mean diurnal IOP at 6 weeks, which was the measure used to compare the efficacy of BBFC+TRAVATAN Z® and TRAVATAN Z® monotherapy in demographic subgroups. Subgroups with n ≤ 10 have been excluded in this report. The comparison was made with descriptive statistics.

 
Results
 

In the full intent-to-treat study population, the mean diurnal IOP at 6 weeks was 17.6 mmHg ±0.4 (Standard Error [SE]) in the BBFC+TRAVATAN Z® group (n=113) and 20.7 mmHg (±0.4 SE) in the TRAVATAN Z® group (n=116); P<0.0001. This improved IOP-lowering efficacy in the BBFC+TRAVATAN Z® group in comparison to the TRAVATAN Z® group was maintained irrespective of age, race and gender. The numerical comparisons of mean diurnal IOP at week 6 in the two treatment groups are shown in Table 1.

 
Conclusions
 

The efficacy of BBFC in lowering mean diurnal IOP, when added to TRAVATAN Z® monotherapy, was maintained at levels similar to the full cohort, in most subgroups, when analyzed by age, race and gender.  

 
Table 1. Comparison of Mean Diurnal IOP (± SE) at week 6 in BBFC + TRAVATAN Z® and TRAVATAN Z® treatment groups within demographic subgroups
 
Table 1. Comparison of Mean Diurnal IOP (± SE) at week 6 in BBFC + TRAVATAN Z® and TRAVATAN Z® treatment groups within demographic subgroups

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×